Scynexis has entered into a research collaboration with Roche to discover and develop novel compounds for central nervous system and metabolic diseases. The transaction will include access by Roche to the Scynexis Medchem-Factory technology and HEOS Hit Explorer Operating System software. This will accelerate the identification of novel leads against Roche's drug targets by producing large, focused, high-purity compound libraries and then utilizing rapid lead optimization to identify clinical candidates.

Specific financial terms were not disclosed. However, Roche will receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for Scynexis technologies and services.

"Scynexis is very pleased with its new relationship with Roche, a premier healthcare company with a long history of impressive innovation. This collaboration is further recognition of Scynexis' patented technologies that will assist in the efforts of Roche scientists, " said Dr. Yves J. Ribeill, President & CEO of Scynexis.